The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class available for children ...

The FDA has granted accelerated approval of the RET inhibitor for all adults with locally advanced or metastatic solid tumours with a RET fusion mutation, two years after giving it a green light ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

[31] XL-184 (BMS 907351, cabozantinib; Exelixis, South San Francisco, CA, USA) is an oral inhibitor of several TK receptors. The primary targets are VEGFR2, RET, c-KIT and MET, which is highly ...